HRT :: Wyeth to pay $1.5 million in hrt Prempro trial

US Philadelphia jury found Wyeth’s hormone replacement therapy (HRT) Prempro was responsible for an Arkansas woman’s breast cancer and ordered the U.S. drugmaker Wyeth to pay $1.5 million in compensatory damages.

The jury found that Wyeth was negligent in failing to provide adequate warnings about the breast cancer risk associated with Prempro.

Mary Daniel, aged 60, of Hot Springs, Arkansas, developed breast cancer after taking Prempro for a 16 month period to treat the symptoms of menopause. Daniel began taking Prempro in late 1999, and was diagnosed with breast cancer in July 2001. She then underwent two surgeries as well as chemotherapy and radiotherapy for the cancer.

The trial heard evidence that Wyeth had known for decades that the drug was linked with an increased risk of developing breast cancer in postmenopausal women but still failed to provide adequate warnings about such a risk, despite the worldwide use of the drug.

Leave a Comment